An RSV Vaccine for Infants

The video discusses RSV, a common respiratory virus affecting vulnerable populations like infants and the elderly. It highlights the significant impact of RSV, with high hospitalization and death rates. The first RSV vaccine was approved by the FDA for older adults, showing high efficacy in clinical trials. Vaccines for infants and maternal vaccinations are also in development, with promising results. The video concludes with the potential public health benefits of these vaccines, despite some concerns about side effects.

What is the primary reason for the urgency in developing an RSV vaccine?

• RSV causes significant hospitalizations and deaths, especially in infants and the elderly.

• RSV is a rare virus with minimal impact.

• RSV is a newly discovered virus.

• RSV only affects people with compromised immune systems.

What was the effectiveness of the RSV vaccine in reducing severe disease in older adults during the clinical trial?

• 50%

• 70%

• 83%

• 94%

What is a notable side effect that requires monitoring after the RSV vaccine becomes available?

• Headaches

• Atrial fibrillation

• Nausea

• Fever

What is the main concern regarding the RSV vaccine for pregnant women?

• High cost

• Severe side effects

• Lack of effectiveness

• Increased risk of preterm birth

Which region approved an RSV vaccine for infants in 2022?

• Asia

• Europe

• South America

• Africa